Company: PACB
Filing Date: 2025-03-17
Form Type: 10-K
Source: 0001299130-25-000061
Chunk: 129

Company: PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
Filing Date: 2025-03-17
Form: 10-K
Item: Item 1
Chunk 129
---
 cash flow informationInterest paid$14,805 $15,687 $14,049 Supplemental disclosure of non-cash investing and financing activitiesInventory transferred to property and equipment $4,194 $3,984 $2,812 Property and equipment transferred to inventory$(2,572)$(7,022)$(715)Right-of-use asset and liability additions and modifications$18,253 $— $— Issuance of common stock in conjunction with convertible notes exchange$36,199 $— $— Issuance of common stock in acquisition of Apton and Omniome$— $76,642 $— Issuance of common stock in connection with Apton liquidity event bonus plan$— $2,111 $— Convertible notes exchange$— $441,000 $— Issuance of common stock following milestone achievement$— $84,761 $—     

See accompanying notes to the consolidated financial statements.

Fiscal 2024 Form 10-K89

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1.  ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIESBusiness OverviewWe are a life science technology company that designs, develops, and manufactures advanced sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems.Our products and technology under development stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing technology and our Sequencing by Binding (SBB) short-read sequencing technology. Our products address solutions across a broad set of applications including human genetics, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. Long-read sequencing was recognized by the journal Nature Methods as its “method of the year” for 2022 for its contributions to biological understanding and future potential. Long-read sequencing has been applied to produce telomere-to-telomere genomes of humans, pangenome references, and has been recognized for its ability to provide more complete views of human variation.Our focus is on creating some of the world's most advanced sequencing systems to provide our customers with the most complete and accurate view of genomes, transcriptomes, and epigenomes.Our customers include academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals